Bayer: Japan approves prostate cancer drug

(CercleFinance.com) - Bayer said on Thursday that its Nubeqa compound had been approved in Japan for the treatment of men with non-metastatic castration-resistant prostate cancer.


The androgen receptor inhibitor, which is being jointly developed with Finland's Orion, is already approved in the US and Brazil and filings in the European Union and other regions are underway.

Bayer also said on Thursday that it has submitted an application in Europe for a pre-filled syringe to administer its eye drug Eylea, currently available in a vial, for five retinal conditions.

If the pre-filled syringe is approved, it would provide physicians with a new option requiring fewer steps to prepare for intravitreal injection.

Copyright (c) 2020 CercleFinance.com. All rights reserved.